PROK.US ProKidney Corp.

Healthcare Biotechnology USA Stocks
2.04 USD
Close of Nov 17, 2026
0.8702 2.65
Market cap
USD 427M
P/E
-
P/B
97.15x
ROE
-
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is PROK.US undervalued?

Graham number

The Graham number of ProKidney Corp. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

ProKidney Corp. fundamental analysis

No fundamental analysis for ProKidney Corp. yet.

ProKidney Corp. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About ProKidney Corp.

ProKidney Corp., a clinical-stage biotechnology company, engages in the development of cell therapies for the treatment of chronic kidney diseases in the United States. The company develops rilparencel, a cell therapy with autologous selected renal cells, which is in Phase III clinical trial for the treatment of advanced chronic kidney disease and type 2 diabetes. It is also involved in the development of cryopreserved versions of rilparencel, including REGEN-006 and REGEN-0…

Full company profile